By examining six regions of the brain at single-molecule resolution, researchers identified layers of tau pathology that were not fully captured by traditional tissue staining.
Research: Nanoscale tau aggregates in Parkinson’s disease. Image credit: Peterschreiber.media / Shutterstock
In a recent study published online as a “press article” in the journal npj parkinson’s diseaseresearchers used single-molecule pull-down (SiMPull) assays and super-resolution microscopy to map the nanoscale distribution of protein aggregates in postmortem human brain tissue.
In this study, we specifically analyzed six different brain regions using tissue from 29 postmortem donors, where sample availability varied by region, and identified distinct populations of hyperintense nanoscopic phosphorylated tau (pTau) aggregates present in the putamen of Parkinson’s disease (PD) cases. The putamen is an area where standard immunohistochemistry showed negligible tau staining in this cohort.
The study further revealed that the length of these nanoscale tau aggregates ranged from 30 to 800 nanometers, while pTau intensity was inversely correlated with immunohistochemical coverage of alpha-synuclein (αSyn) in the amygdala. Furthermore, although tau aggregate burden was on average the highest among the five PD cases with documented dementia, single-molecule assays did not identify PD-specific populations of nanoscale αSyn species.
background
Classic neuropathological evaluation of Parkinson’s disease (PD) usually focuses on the aggregation of α-synuclein into insoluble Lewy bodies and the loss of dopaminergic cells in the substantia nigra. However, new biophysical studies suggest that these large inclusions may be late-stage sequestration products rather than the main toxic species.
These studies indicate the existence of smaller, more soluble intermediate species called nanoscopic aggregates. Growing experimental evidence suggests that these nanoscopic aggregates may be more toxic than mature fibrils, but their effects in the human brain remain uncertain.
Unfortunately, postmortem pathology of tau has been documented in up to 50% of PD dementia cases, but conventional immunohistochemistry (IHC) cannot reliably separate or characterize the smallest subdiffractive aggregates. As a result, it remained unclear whether nanoscale tau accumulation is a unique feature of PD or reflects the co-occurrence of age-related tauopathies.
About research
This study aimed to elucidate their pathological dynamics by systematically profiling soluble nanoscopic aggregates and insoluble inclusions across six major brain regions: hippocampus, amygdala, substantia nigra, putamen, frontal cortex, and occipital cortex.
The main sample cohort for this study consisted of 29 postmortem cases, or donated brains, which the authors divided into three distinct study groups: 1. idiopathic PD patients (n = 14; 5 with documented dementia), 2. non-PD control cases with age-related tau pathology (AR-tau; n = 7, primarily Braak stage III), and 3. controls with minimal neuropathology (Braak stage III) 0-II; 8). Additionally, nine Alzheimer’s disease (AD) putamen samples (Braak stages III to VI) were evaluated, allowing cross-disease benchmarking.
To differentiate aggregated populations, the researchers combined DAB immunohistochemistry on formalin-fixed tissue with single-molecule pulldown (SiMPull) assays performed on fresh-frozen soluble tissue fractions.
Quantitative endpoints of this study evaluated aggregate density, estimated detected antibody binding per aggregate as an intensity-based measure of aggregate size, colocalization of polychromatic fluorophores (HT7 for total tau, AT8 and pT181 for pTau, Syn211 for αSyn), and super-resolution length measurements of DNA-PAINT. The presence of putamen pTau aggregates was further examined in situ in three PD samples and three control samples using stimulated emission depletion (STED) microscopy.
SiMPull workflow and output for characterizing protein aggregates. (a) Overview of postmortem brain tissue cohort. Due to the reduced sample size of frozen tissue, SN was emphasized. (b) IHC was used to study large insoluble inclusion bodies. (c) Schematic diagram of SiMPull used for nanoscopic aggregate detection. SiMPull excludes monomers from detection by using identical capture and detection antibodies. (d) Example of diffraction-limited imaging using a tau-SiNaP aggregate standard. Aggregate density was significantly correlated with tau-SiNaP concentration (Pearson correlation). Each point represents the average of 12 FOVs and three well replicates, and error bars represent mean ± standard deviation. (e) Example “auto” contrast-adjusted image of HT7 dipeptide, tau-SiNaP, and the corresponding aggregation intensity distribution. (f) Example images of HT7 imaged on channel (Ch) 1 and AT8 imaged on Ch2. White arrows indicate the same object in each channel and colocalized merged images. (g) Example DNA-PAINT image from one PD human brain sample. Insets (i) and (ii) are magnified views of super-resolved pTau aggregates. HIP = hippocampus. AMYG = amygdala. PUT = putamen; SN = substantia nigra. FC = frontal cortex. OC = occipital cortex; SiNaP = silica nanoparticles. FOV = field of view. pTau = phosphorylated tau.
Research results
SiMPull analysis in this study revealed that total tau intensity was bimodal. Low-intensity population peaks (1–10 antibodies/aggregates) were interpreted to correspond to physiological multimers. In high-intensity populations (10–1,000 antibodies per population), disease-associated species were instead prominent.
Of note, while standard IHC had negligible tau staining within the putamen, SiMPull confirmed a previously undetected PD-associated increase in hyperintense pTau aggregates within the putamen (p = 0.007 vs. control; p = 0.030 vs. AR-tau).
DNA-PAINT super-resolution imaging confirmed that these putamen pTau aggregates form fibrillar structures ranging from 30 to 800 nm in length. In cross-disease comparisons with AD putamen tissue, mid-Braak stage AD (III-IV) showed predominantly low-intensity total tau aggregates, whereas advanced AD (V-VI) showed higher pTau aggregate intensity than PD (p = 0.003) and mid-stage AD (p = 0.015).
These findings support the possibility that nanoscale tau accumulation precedes the formation of visible inclusions. In the amygdala of PD cases, pTau SiMPull intensity was inversely correlated with αSyn IHC coverage (ρ = -0.61, p = 0.04), suggesting a complex relationship between Lewy body pathology and nanoscale tau accumulation, although the mechanism and direction of this relationship remain unclear.
Furthermore, descriptive subgroup comparisons showed that PD cases with dementia had the highest mean nanoscale pTau aggregate burden in both the medial temporal lobe and putamen. Conversely, αSyn SiMPull did not identify distinct nanoscopic aggregate populations in PD brains. Importantly, 87.8% of the αSyn signal in PD was bound to less than five detection antibodies and was interpreted as a low-order physiological multimer, consistent with dimers and tetramers detected using native PAGE.
conclusion
This study provides evidence that the burden of tau pathology in Parkinson’s disease may have been underestimated by traditional immunohistochemical methods. The findings revealed that soluble nanoscale pTau aggregates were detected in the putamen despite negligible visible tau inclusions, suggesting that these species may precede inclusion formation.
The authors highlight that although these findings suggest that nanoscale tau may contribute to nigrostriatal neurodegeneration and cognitive decline in some patients with advanced PD, this study is limited by a cross-sectional postmortem design, modest sample size within regional subgroups such as the substantia nigra, and insufficient clinical data to examine associations with movement disorders.
However, beyond these caveats, the identification of subdiffractive pTau species highlights that nanoscale tau is a potential target for future disease modification studies, although reproducible and mechanistic evidence is needed to establish its therapeutic relevance.
Reference magazines:
- Layburn, F., Böken, D., Zhang, Y.P., Halliday, K., Rodgers, D., Kedia, S., Nolan, G., Kahanawita, L., Patel, B., Quaegebeur, A., Williams-Gray, C.H., & Klenerman, D. (2026). Nanoscale tau aggregates in Parkinson’s disease. Npj Parkinson’s disease. Doi: 10.1038/s41531-026-01489-3, https://www.nature.com/articles/s41531-026-01489-3
